Published in Exp Cell Res on May 15, 2005
Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol (2012) 1.73
Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol (2009) 1.69
Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc Natl Acad Sci U S A (2008) 1.15
PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol (2006) 1.13
Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int (2007) 1.09
Characterization of the early proliferative response of the rodent bladder to subtotal cystectomy: a unique model of mammalian organ regeneration. PLoS One (2012) 1.03
Differential regulation of growth-promoting signalling pathways by E-cadherin. PLoS One (2010) 0.96
Functional expression of purinergic P2 receptors and transient receptor potential channels by the human urothelium. Am J Physiol Renal Physiol (2013) 0.91
A novel bidirectional positive-feedback loop between Wnt-β-catenin and EGFR-ERK plays a role in context-specific modulation of epithelial tissue regeneration. J Cell Sci (2014) 0.87
Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer. J Cell Physiol (2011) 0.86
Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. PPAR Res (2009) 0.84
From pathway to population--a multiscale model of juxtacrine EGFR-MAPK signalling. BMC Syst Biol (2008) 0.83
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. Int J Mol Sci (2014) 0.82
Differentiation-associated reprogramming of the transforming growth factor β receptor pathway establishes the circuitry for epithelial autocrine/paracrine repair. PLoS One (2012) 0.79
Sources of variability in cytosolic calcium transients triggered by stimulation of homogeneous uro-epithelial cell monolayers. J R Soc Interface (2015) 0.77
Characterization and classification of adherent cells in monolayer culture using automated tracking and evolutionary algorithms. Biosystems (2016) 0.75
Sleeping beauty: awakening urothelium from its slumber. Am J Physiol Renal Physiol (2017) 0.75
Amphiregulin enhances intercellular adhesion molecule-1 expression and promotes tumor metastasis in human osteosarcoma. Oncotarget (2015) 0.75
New Amniotic Membrane Based Biocomposite for Future Application in Reconstructive Urology. PLoS One (2016) 0.75
Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium. Cell Death Differ (2017) 0.75
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol (2004) 5.84
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res (2013) 2.45
Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics (2004) 2.43
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics (2003) 2.17
Expression and localisation of aquaporin water channels in human urothelium in situ and in vitro. Eur Urol (2008) 1.92
Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics (2005) 1.69
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney Int (2013) 1.61
Recreational ketamine: from pleasure to pain. BJU Int (2011) 1.54
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem (2005) 1.46
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population. Psychol Psychother (2002) 1.40
The majority of the in vitro erythroid expansion potential resides in CD34(-) cells, outweighing the contribution of CD34(+) cells and significantly increasing the erythroblast yield from peripheral blood samples. Haematologica (2010) 1.39
Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol (2009) 1.38
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet (2011) 1.34
Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci (2004) 1.29
Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res (2003) 1.26
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res (2007) 1.25
Is tissue engineering and biomaterials the future for lower urinary tract dysfunction (LUTD)/pelvic organ prolapse (POP)? Neurourol Urodyn (2011) 1.20
A Rasch and factor analysis of the Functional Assessment of Cancer Therapy-General (FACT-G). Health Qual Life Outcomes (2007) 1.19
The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology (2008) 1.18
Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol Biosyst (2008) 1.18
The virtual cell--a candidate co-ordinator for 'middle-out' modelling of biological systems. Brief Bioinform (2009) 1.17
CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol (2008) 1.17
Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol (2003) 1.16
Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol (2004) 1.15
Development and characterisation of a full-thickness acellular porcine bladder matrix for tissue engineering. Biomaterials (2006) 1.15
PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol (2006) 1.13
Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2). Haematologica (2010) 1.12
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. Fam Pract (2004) 1.11
Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics (2006) 1.10
Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol (2002) 1.10
Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int (2007) 1.09
Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer (2010) 1.09
Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication. J Clin Oncol (2011) 1.09
Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08
Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age. Proteomics Clin Appl (2013) 1.08
Characterisation of electrospun polystyrene scaffolds for three-dimensional in vitro biological studies. Biomaterials (2006) 1.07
Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res (2010) 1.07
Calcium signalling in wound-responsive normal human urothelial cell monolayers. Cell Calcium (2008) 1.07
The relationship between the mechanical properties and cell behaviour on PLGA and PCL scaffolds for bladder tissue engineering. Biomaterials (2008) 1.05
Synergistic roles for the Map and Tir effector molecules in mediating uptake of enteropathogenic Escherichia coli (EPEC) into non-phagocytic cells. Cell Microbiol (2003) 1.05
Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics (2008) 1.04
An integrated agent-mathematical model of the effect of intercellular signalling via the epidermal growth factor receptor on cell proliferation. J Theor Biol (2006) 1.03
A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics (2011) 1.02
A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst (2010) 1.02
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Single linkage group per chromosome genetic linkage map for the horse, based on two three-generation, full-sibling, crossbred horse reference families. Genomics (2005) 0.99
Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun (2005) 0.99
Deregulation of Rab and Rab effector genes in bladder cancer. PLoS One (2012) 0.97
Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer (2005) 0.96
Differential regulation of growth-promoting signalling pathways by E-cadherin. PLoS One (2010) 0.96
Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res (2008) 0.96
The small GTPase Rif is an alternative trigger for the formation of actin stress fibers in epithelial cells. J Cell Sci (2010) 0.95
Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One (2012) 0.95
Generation of a functional, differentiated porcine urothelial tissue in vitro. Eur Urol (2008) 0.93
Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol (2008) 0.92
The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res (2003) 0.92
Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics (2006) 0.92
Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer (2014) 0.92
Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics (2009) 0.91
Functional expression of purinergic P2 receptors and transient receptor potential channels by the human urothelium. Am J Physiol Renal Physiol (2013) 0.91
Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol Cancer Res (2008) 0.90
Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int (2013) 0.90
Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol (2002) 0.90
Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics (2009) 0.89
Differential expression of Oct4 variants and pseudogenes in normal urothelium and urothelial cancer. Am J Pathol (2013) 0.89
Characteristic phenotypes associated with congenital dyserythropoietic anemia (type II) manifest at different stages of erythropoiesis. Haematologica (2013) 0.89
Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl (2013) 0.89
Review: tissue engineering of the urinary bladder: considering structure-function relationships and the role of mechanotransduction. Tissue Eng (2006) 0.88
Tissue engineering potential of urothelial cells from diseased bladders. J Urol (2011) 0.88
Immortalisation of normal human urothelial cells compromises differentiation capacity. Eur Urol (2011) 0.88
Cyclin E is recruited to the nuclear matrix during differentiation, but is not recruited in cancer cells. Nucleic Acids Res (2010) 0.87
Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same? Proteomics (2008) 0.87
Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev (2013) 0.87
Key clinical issues in renal cancer: a challenge for proteomics. World J Urol (2007) 0.87
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol (2013) 0.87
Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions. Ann Clin Biochem (2011) 0.87
Aquaporin expression contributes to human transurothelial permeability in vitro and is modulated by NaCl. PLoS One (2012) 0.86
Development of an advanced database for clinical trials integrated with an electronic patient record system. Comput Biol Med (2011) 0.86
Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics (2003) 0.86
The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst (2002) 0.85
Proteomic profiling using mass spectrometry--does normalising by total ion current potentially mask some biological differences? Proteomics (2008) 0.85
Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. PPAR Res (2009) 0.84
Towards control of smooth muscle cell differentiation in synthetic 3D scaffolds. Biomaterials (2008) 0.84
The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res (2004) 0.84
Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol (2008) 0.84
Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. Eur J Cancer (2012) 0.84